Osteopatia como meio terapêutico nas disfunções temporomandibulares e dores orofaciais

Pós-graduação em Biopatologia Bucal - ICT

A característica universal de Leibniz: contextos, trajetórias e implicações

Pós-graduação em Educação Matemática - IGCE

Avaliação da gentamicina aplicada em ovos de aves reprodutoras pesadas e seu efeito residual nos tecidos

Pós-graduação em Medicina Veterinária - FCAV

O olhar como experiência: a pintura

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

A articulação entre política externa e política de defesa no Brasil: uma Grande Estratégia inconclusa

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Distribuição de bivalve invasor Limnoperna fortunei (Dunker, 1857) na Bacia do Rio Prata após vinte anos (1991-2014) de sua introdução na America do Sul

Pós-graduação em Ciências Biológicas (Zoologia) - IBB

Diversidade patogênica em isolados de Thielaviopsis paradoxa provenientes de diferentes áreas produtoras de cana-de-açúcar

Pós-graduação em Agronomia (Genética e Melhoramento de Plantas) - FCAV

Biologia floral de Zeyheria tuberculosa (Bignoniaceae)

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Compartilhamento de informações entre os Sistemas de Cadastro e de Registro de Imóveis utilizando um SIG cadastral

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Uso do soro autólogo condicionado e do plasma rico em plaquetas na terapia ortopédica de equinos

Musculoskeletal injuries that occur in horses during sports activities are often disabling and require a long period of treatment and rehabilitation, most resulting in scar tissue, predisposing to recurrence. In search of more effective therapies and tissue regeneration, studies have been carried out with blood derivatives - platelet rich plasma and autologous conditioned serum. In spite of both being blood-derived therapies, platelet rich plasma and autologous conditioned serum are distinct products, with equally distinct indications for their use. Platelet rich plasma shows promising results in ligament and tendon injuries in clinical and experimental trials. This occurs also in osteoarticular lesions with both hemoderivates, autologous conditioned serum and platelet rich plasma. This review aims to present clinical and experimental studies (in vivo and in vitro) in the equine species, as an aid for an appropriate therapeutic choice, when hemoderivates are considered for treatment of musculoskeletal lesions.

Diretrizes de conduta e tratamento de síndromes febris periódicas associadas à criopirina (Criopirinopatias–CAPS)

To establish guidelines based on cientific evidences for the management of cryopyrin associated periodic syndromes. The Guideline was prepared from 4 clinical questions that were structured through Pico (Patient, Intervention or indicator, Comparison and Outcome), to search in key primary scientific information databases. After defining the potential studies to support the recommendations, these were graduated considering their strength of evidence and grade of recommendation. 1215 articles were retrieved and evaluated by title and abstract; from these, 42 articles were selected to support the recommendations. 1. The diagnosis of Caps is based on clinical history and clinical manifestations, and later confirmed by genetic study. Caps may manifest itself in three phenotypes: FCAS (mild form), MWS (intermediate form) and Cinca (severe form). Neurological, ophthalmic, otorhinolaryngological and radiological assessments may be highly valuable in distinguishing between syndromes; 2. The genetic diagnosis with NLRP3 gene analysis must be conducted in suspected cases of Caps, i.e., individuals presenting before 20 years of age, recurrent episodes of inflammation expressed by a mild fever and urticaria; 3. Laboratory abnormalities include leukocytosis and elevated serum levels of inflammatory proteins; 4. Targeted therapies directed against interleukin-1 lead to rapid remission of symptoms in most patients. However, there are important limitations on the long-term safety. None of the three anti-IL-1β inhibitors prevents progression of bone lesions.